Hematologic Cancer

Regional Health is involved in hematologic cancer research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.


E1A11 (ENDURANCE)
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasome (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology

 


NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology

 


RU051417I
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology